Vascular Biogenics (VBLT) Stock Surges On Topline Results From VB-111 Phase 2 Trial

Vascular Biogenics Ltd (VBLT) is a big mover this session, as its shares are up nearly 25%. The surge came after the biotechnology company announced top-line interim results from its ongoing Phase 2 study of VB-111 in patients with recurrent glioblastoma (rGBM), which demonstrated a statistically significant improvement in overall survival in patients treated with […] View the full post at: Vascular Biogenics (VBLT) Stock Surges On Topline Results From VB-111 Phase 2 Trial Related posts: Casino capitalism on trial California’s 1st-Time Home Buyer Affordability Surges in QI Congress To Hold Hearing on the Circumstances Behind Thursday’s Stock Market Plunge